Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Titel:
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Auteur:
Hofman, Michael S Emmett, Louise Sandhu, Shahneen Iravani, Amir Buteau, James P Joshua, Anthony M Goh, Jeffrey C Pattison, David A Tan, Thean Hsiang Kirkwood, Ian D Ng, Siobhan Francis, Roslyn J Gedye, Craig Rutherford, Natalie K Weickhardt, Andrew Scott, Andrew M Lee, Sze-Ting Kwan, Edmond M Azad, Arun A Ramdave, Shakher Redfern, Andrew D Macdonald, William Guminski, Alex Hsiao, Edward Chua, Wei Lin, Peter Zhang, Alison Yan Stockler, Martin R Williams, Scott G Martin, Andrew J Davis, Ian D